Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | PAK1 | Q13153 | 7/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | STK4 | Q13043 | 1/20 | 0.41 |
| ▸ | STK3 | Q13188 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | SUV39H1 | O43463 | 2/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.39 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.38 |
| ▸ | KIT | P10721 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4582930 | 0.93 | CYP1A2 (0.53) | CYP1A2CYP2D6PAK1PDGFRBSTK4 | |
| SCHEMBL4583456 | 0.87 | ALDH1A1 (0.51) | — | |
| SCHEMBL4583794 | 0.87 | CNR1 (0.49) | CYP1A2CYP2D6PAK1PDGFRBSTK4 | |
| SCHEMBL4583193 | 0.85 | CYP1A2 (0.50) | CYP1A2CYP2D6PAK1PDGFRBSTK4 | |
| SCHEMBL4583403 | 0.83 | CYP1A2 (0.52) | CYP1A2CYP2D6PAK1PDGFRBSTK4 | |
| SCHEMBL4022823 | 0.83 | CYP1A2 (0.53) | CYP1A2CYP2D6PAK1PDGFRBSUV39H1 | |
| SCHEMBL4583933 | 0.82 | CNR1 (0.49) | CYP1A2CYP2D6PAK1PDGFRBSTK4 | |
| SCHEMBL4583914 | 0.82 | PDGFRB (0.45) | PDGFRB | |
| SCHEMBL4582322 | 0.79 | ALDH1A1 (0.54) | — | |
| SCHEMBL4581570 | 0.79 | DRD4 (0.42) | PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | claimed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | CYP1A2 88/4885CYP2D6 247/4885PAK1 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.